|
|
|
|
|
|
|
|
|
|
|
01.04.26 - 12:01
|
Addition of Non-Executive Director to TP Aerospace (Cision)
|
|
|
Copenhagen, April 1, 2026 – At an extraordinary general assembly held today, the shareholders of TP Aerospace resolved to appoint Tilde Kejlhof as a new member of the Board of Directors.
Tilde Kejlhof brings extensive experience in finance and production. She joins from SP Group, a company listed on the Copenhagen Stock Exchange, where she currently serves as Senior Vice President with a focus on strategic projects. Prior to this role, she held the position of Chief Financial Officer.
Tilde Kejlhof will also assume the role of Chair of the Audit Committee.
TP Aerospace welcomes...
|
|
|
26.03.26 - 14:48
|
Trading by management and close relations of management (GlobeNewswire EN)
|
|
|
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B....
|
|
|
|
|
23.03.26 - 13:57
|
Trading by management and close relations of management (GlobeNewswire EN)
|
|
|
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B....
|
|
|
|
|
16.03.26 - 11:42
|
Momentum statt Bauchgefühl: wikifolio-Trader Marco Schai setzt auf Kursdynamik - "Invest first, investigate later" (BRN)
|
|
|
Marco Schai handelt im wikifolio Refresh mit einer klaren Momentum-Strategie. Der Trader sucht gezielt Aktien mit stark steigenden Kursen und analysiert erst danach das Unternehmen. Seine Devise lautet: "Invest first, investigate later." Über einen Screener identifiziert er Werte, die sich dynamisch entwickeln oder nach positiven Gewinnüberraschungen stark steigen. Anschließend prüft er Geschäftsmodell, Wachstum und Perspektiven. Trotz rund 200 Positionen konzentriert sich das Portfolio auf etwa 30 größere Kernwerte, die rund die Hälfte des Kapitals ausmachen. Zu den aktuellen Schwergewichten gehört Proto Labs. Der US-Spezialist für schnelle Prototypenfertigung überraschte zuletzt mit starken Quartalszahlen und einer Gewinnüberraschung von rund 25 %. Auch Hims & Hers bleibt im Depot. Nach einem massiven Kursrückgang sorgte eine Einigung mit Novo Nordisk im Streit um Abnehmspritzen für einen Kurssprung von etwa 40 %. Zusätzlich setzt Schai auf CF Industries. Der Düngemittelhersteller profit...
|
|
|
13.03.26 - 10:00
|
Novonesis issues EUR 1.7 billion senior unsecured notes (GlobeNewswire EN)
|
|
|
On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly established EUR 4 billion Euro Medium Term Note (EMTN) Programme, dated March 10, 2026....
|
|
|
11.03.26 - 13:42
|
Trading by management and close relations of management (GlobeNewswire EN)
|
|
|
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B....
|
|
|
09.03.26 - 22:36
|
Novonesis named a Great Employer to Work For in North Carolina (GlobeNewswire EN)
|
|
|
Franklinton, North Carolina, March 09, 2026 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, has been named a 2026 Great Employer to Work for in North Carolina by Best Companies Group (BCG), marking the company's first time earning this prestigious recognition. BCG is a trusted leader in workplace culture research and recognition, distinguishing top companies around the United States for more than 20 years. The honor is based entirely on confidential employee feedback and a comprehensive evaluation of workplace practices, culture, and leadership. ...
|
|
|
|
|
27.02.26 - 10:27
|
Trading by management and close relations of management (GlobeNewswire EN)
|
|
|
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B....
|
|
|
26.02.26 - 17:06
|
Trading by management and close relations of management (GlobeNewswire EN)
|
|
|
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B....
|
|
|
26.02.26 - 12:03
|
Invitation to the 2026 Annual General Meeting (GlobeNewswire EN)
|
|
|
The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark....
|
|
|
26.02.26 - 11:27
|
Trading by management and close relations of management (GlobeNewswire EN)
|
|
|
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B....
|
|
|
26.02.26 - 06:12
|
Novozymes Reports Climb In Q4 Bottom Line (AFX)
|
|
|
BRUSSELS (dpa-AFX) - Novozymes (NVZMF.PK) reported earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings came in at EUR122.8 million, or EUR1.25 per ......
|
|
|
|